AI to Navigate FDA Medical Device Regulations in the Age of Foundation Models

Why the AI hype has not solved regulatory navigation yet

Large‑language models and other foundation models have made it possible to search and summarise FDA guidance at unprecedented speed. However, subject matter experts note that they do not automatically translate to regulatory understanding. Unlike industries with straightforward rules, medical device regulations depend on interpretation and context. Guidance documents are updated frequently, datasets are fragmented across divisions and precedent decisions, and the FDA applies a risk‑based oversight framework: higher‑risk devices require more rigorous evidence than low‑risk devices. Software functions intended to support – but not replace – clinical decision‑making may be exempt from device classification provided that the basis for recommendations is clear.

The challenge for AI tools is not accessing information but presenting it in a way that regulatory reviewers trust and can independently verify. The Bipartisan Policy Center explains that the FDA’s “Good Machine Learning Practice” principles emphasise transparency, data quality, representative datasets, and ongoing model maintenance. Decision‑support software must allow humans to review and understand the basis for recommendations. Foundation models can help by generalising across diverse datasets and reducing bias, but they must also address known pitfalls such as hallucinations and lack of explainability. Experts at the FDA Law Blog note that hallucination rates are decreasing yet urge guardrails, including transparency and explainability, to make AI trustworthy.

What navigating FDA regulations actually means

When executives and engineers say they want “AI to navigate FDA medical device regulations,” they often imagine a system that answers questions. In reality, navigation requires decisions, not just information retrieval. Teams must determine device classification, choose a regulatory pathway (510(k), De Novo, PMA), map submission requirements, and plan clinical evidence. Misclassification or late pathway changes can extend timelines; 510(k) submissions now exceed 1 000 pages, so planning should begin early. Regulatory planning during design and development helps teams anticipate how design changes affect risk and which data the FDA will expect.

What an AI system must do to be regulatory‑grade

An AI system designed to navigate FDA regulations must support this decision‑making workflow. Key requirements include:

1. Structured reasoning – The system should model regulatory decision trees (e.g., classification rules, predicate selection, benefit–risk factors), not just perform text search. FDA’s risk‑based oversight means different paths require different evidence.
2. Transparent recommendations – Reviewers must see citations to guidance documents, precedent decisions and underlying data for each recommendation. Regulations on clinical decision support emphasise that providers must understand the basis for recommendations.
3. Precedent and context – To maintain regulatory intent, AI must incorporate precedent (e.g., similar cleared devices, advisory committee decisions). Talencio’s 2025 analysis suggests that executives should establish regulatory‑intelligence teams to monitor policy changes and judicial decisions and use scenario planning to anticipate their impact.
4. Explainability and guardrails – Good Machine Learning Practice calls for representative data, solid engineering, monitoring performance over time, and accounting for human‑AI interactions. The FDA Law Blog emphasises the need for transparent, interpretable AI and warns against hype.

How Guideways could apply this

Guideways’ platform appears to embed decision‑support agents like FDA Sherpa, Reviewer and Researcher. To illustrate best practices:

• FDA Sherpa could provide a structured classification wizard that walks users through device type, risk factors and potential predicates. It should link each recommendation to relevant CFR sections or guidance documents and highlight assumptions.
• FDA Reviewer could perform gap analysis against the appropriate pathway, flagging missing evidence and inconsistent data. The system must show the source requirement (e.g., a specific 510(k) requirement) and allow the user to override or justify differences. Early, transparent interaction with the FDA is critical; pre‑submission meetings de‑risk submissions and shorten review times.
• FDA Researcher should synthesise precedent, including predicate devices and advisory decisions, and help teams understand how regulatory changes (e.g., new leadership, ISO 13485 adoption or cybersecurity guidance) affect strategy.

What to expect in the next two years

AI assistance will not replace regulatory expertise; rather, it will make it more scalable. Guidance is increasingly emphasising collaboration, transparency and early engagement. Companies that invest in AI systems with traceability, decision‑support logic and regulatory intelligence will have a strategic advantage.